Michael A. Schwarzschild, MD, PhD, is a neurologist at Massachusetts General Hospital and Julieanne Dorn Professor of Neurology at Harvard Medical School. He pursued doctoral studies on tyrosine hydroxylase neurochemistry at HMS and then neurology residency and Parkinson’s disease fellowship training at MGH. He has developed a translational research program focusing on purines like adenosine, caffeine and urate, and on gene (e.g., LRRK2) -environment interactions in animal models and clinical studies of Parkinson’s disease (PD). He directs the Molecular Neurobiology Lab at the MassGeneral Institute for Neurodegenerative Disease where his interdisciplinary research program spans the neurobiology, epidemiology, and clinical science of Parkinson’s.
In 2018, he was elected to a second six-year term leading the Parkinson Study Group (PSG), a consortium of North American clinical trial sites and investigators dedicated to finding improved treatments for people with Parkinson’s. At MGH, he cares for patients with PD and their families in a weekly movement disorders clinic.